Baker McKenzie recently provided legal advice to a large group of shareholders, consisting of over 90 individuals, regarding the sale of their shares in APEIRON Biologics AG to Ligand Pharmaceuticals Incorporated. APEIRON Biologics AG is a prominent biotechnology company that focuses on developing immunotherapies for cancer and other severe illnesses. Through this sale, APEIRON will enhance its presence in the global market. The transaction was finalized in mid-July 2024.
Gerhard Hermann, a partner at Baker McKenzie and the leader of the transaction team, expressed his satisfaction with the outcome, stating, “We are delighted to have guided the shareholders of APEIRON Biologics AG through this significant deal.” The team at Baker McKenzie consisted of experts in mergers and acquisitions, corporate law, taxation, and intellectual property, who collaborated to ensure a smooth and effective execution of all transaction components.
This transaction marks a significant milestone for APEIRON Biologics AG and highlights the company’s commitment to advancing innovative treatments for various diseases, particularly cancer. The expertise and dedication of the Baker McKenzie team were crucial in facilitating this complex transaction and ensuring that the interests of the shareholders were protected throughout the process.
In addition to providing legal counsel, Baker McKenzie also offers a newsletter that delivers the latest articles directly to subscribers. By subscribing to the newsletter, readers can stay informed about recent developments in the legal and business sectors. Signing up for the newsletter signifies agreement with the Terms of Use and an understanding of the data practices outlined in the Privacy Policy. Subscribers have the option to unsubscribe at any time to manage their preferences.
Overall, the sale of APEIRON Biologics AG shares to Ligand Pharmaceuticals Incorporated represents a significant achievement for both companies and underscores the importance of legal expertise in navigating complex transactions. The collaboration between the shareholders, APEIRON Biologics AG, and Baker McKenzie demonstrates the value of strategic partnerships in achieving successful outcomes in the biotechnology industry. This transaction serves as a testament to the potential for growth and innovation in the field of immunotherapy and highlights the importance of legal support in facilitating such advancements.
